Campbell Shane Alden 4

What Happened

• Shane Alden Campbell, Senior Vice President, Proprietary Segment at West Pharmaceutical Services (WST), had restricted stock units (RSUs) vest on May 12, 2026. Two RSU tranches converted into a total of 769.588 shares (295.995 + 473.593).
• To cover tax withholding on the vesting, 219.256 shares (84.329 + 134.927) were surrendered at a reported price of $312.07 per share, yielding approximately $68,424 in tax/withholding proceeds. Net shares delivered to Campbell after withholding were 550.332 shares.
• These were vesting/conversion events (derivative conversion), not open-market sales or purchases.

Key Details

• Transaction date: May 12, 2026; Form 4 filed May 14, 2026 (timely filing).
• Transaction codes: M = exercise/conversion of derivative (RSU conversion); F = payment of exercise price or tax liability (shares withheld for taxes).
• Reported per-share price used for withholding: $312.07; total withheld value reported ≈ $68,424.
• Shares owned after the transaction: not specified in the provided filing data.
• Footnotes: F1 notes RSUs convert one-for-one to common stock. F2/F3: the RSUs were originally granted on May 12, 2025 (1,182 RSUs and 1,891 RSUs, each vesting in four equal annual installments plus dividend equivalents).

Context

• This is a routine vested-RSU settlement with cashless/share-withholding to satisfy tax obligations — not a signal of an open-market sale or purchase. For retail investors, vesting events are compensation-related and do not necessarily reflect the insider’s trading view.